anti-NY-ESO1/LAGE-1A TCR/scFv anti-CD3 IMCnyeso

{
  "id": "MLC-T-ONC-010935",
  "term": "anti-NY-ESO1/LAGE-1A TCR/scFv anti-CD3 IMCnyeso",
  "field": "Oncology and biomedicine",
  "definition": "A bispecific molecule composed of a soluble, affinity-enhanced T-cell receptor (TCR) specific for human leukocyte antigen A2 (HLA-A2)-restricted cancer-testis antigens (CTAs) NY-ESO-1 and L antigen family member 1 isoform A (LAGE-1A; LAGE-A1; CT6.2a), fused to a single-chain variable fragment (scFv) specific for the T-cell surface antigen CD3, with potential immunomodulating and antineoplastic activities. Upon infusion, anti-NY-ESO1/LAGE-1A TCR/scFv anti-CD3 IMCnyeso specifically targets and binds with its TCR moiety to NY-ESO-1 and/or LAGE-1A expressed on tumor cells and with its scFv moiety to CD3 expressed on T-cells. This crosslinks tumor cells and T-cells, re-directs and activates T cells, and results in a cytotoxic T-lymphocyte (CTL)-mediated destruction of NY-ESO-1 and/or LAGE-1A-positive tumor cells. NY-ESO-1 and LAGE-1A, members of the cancer-testis antigen (CTA) family, are overexpressed on the surface of various tumor cell types; they share a specific HLA-A*0201 epitope, 157-165, which is expressed on certain tumor cell types while its expression is not found on normal, healthy cells.",
  "synonyms": [
    "bispecific NY-ESO-1- and LAGE-1A-specific TCR/anti-CD3",
    "HLA- A*0201-restricted NY-ESO-1- and LAGE-1A-specific soluble TCR/anti-CD3 bispecific molecule"
  ],
  "references": [
    "National Cancer Institute Thesaurus"
  ],
  "url": "https://mlchart.com/terminology/oncology/anti-ny-eso1-lage-1a-tcr-scfv-anti-cd3-imcnyeso/"
}